2 news items
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REPL
23 May 24
selected for oral presentation, including an updated presentation of investigator-assessed 12-month data from the IGNYTE clinical trial of RP1
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
REPL
16 May 24
have exciting milestones in the coming months, including sharing the investigator-assessed 12-month IGNYTE data at ASCO and then the official primary
- Prev
- 1
- Next